Andreas Pfützner

ORCID: 0000-0003-2385-0887
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes Management and Research
  • Diabetes Treatment and Management
  • Metabolism, Diabetes, and Cancer
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Diabetes and associated disorders
  • Pancreatic function and diabetes
  • Adipokines, Inflammation, and Metabolic Diseases
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Diet and metabolism studies
  • Lipoproteins and Cardiovascular Health
  • Peroxisome Proliferator-Activated Receptors
  • Pharmacology and Obesity Treatment
  • Diabetes Management and Education
  • Thermoregulation and physiological responses
  • Pharmaceutical studies and practices
  • Adipose Tissue and Metabolism
  • Cardiovascular Function and Risk Factors
  • Spectroscopy Techniques in Biomedical and Chemical Research
  • Regulation of Appetite and Obesity
  • Cardiovascular Health and Disease Prevention
  • Heart Rate Variability and Autonomic Control
  • Electrochemical sensors and biosensors
  • Pain Mechanisms and Treatments
  • Botulinum Toxin and Related Neurological Disorders
  • Growth Hormone and Insulin-like Growth Factors

TH Bingen University of Applied Sciences
2009-2025

University of Luxembourg
2019-2025

University of Vienna
2022

Hochschule Bonn-Rhein-Sieg
2004-2019

Johnson & Johnson (United States)
2019

California Institute for Biomedical Research
2019

Institut für Klinische Forschung und Entwicklung
2006-2016

Orthopädische Praxis
2015

Weatherford College
2007-2014

Johannes Gutenberg University Mainz
1995-2010

Aim: The study aim was to evaluate the efficacy and safety of initial combination therapy with saxagliptin + metformin vs. or monotherapy in treatment‐naïve patients type 2 diabetes (T2D) inadequate glycaemic control. Methods: In this multicentre, randomized, double‐blind, active‐controlled phase 3 trial, 1306 T2D ≥18 ≤77 years, glycosylated haemoglobin (HbA1c) ≥8 ≤12%, fasting C‐peptide concentration ≥1.0 ng/ml, body mass index ≤40 kg/m were randomized receive 5 mg 500 mg, 10 placebo for 24...

10.1111/j.1463-1326.2009.01056.x article EN Diabetes Obesity and Metabolism 2009-05-06

Insulin lispro, an insulin analog recently developed particularly for mealtime therapy, has a fast absorption rate and short duration of action. We compared lispro regular human in the treatment 1,008 patients with IDDM. The study was 6-month randomized multinational (17 countries) multicenter (102 investigators) clinical trial performed open-label crossover design. injected immediately before meal, 30–45 min meal. Throughout study, postprandial rise serum glucose significantly lower during...

10.2337/diab.46.2.265 article EN Diabetes 1997-02-01

Patients with type 2 diabetes mellitus are at high risk of cardiovascular disease. Carotid intima-media thickness (IMT) is a strong predictor myocardial infarction and stroke.We compared the effects pioglitazone-based therapy (45 mg/d) glimepiride-based treatment (2.7+/-1.6 for 12 24 weeks on metabolic control (HbA1c), insulin resistance (homeostasis model assessment), carotid IMT (B-mode ultrasonography) in randomized controlled study 173 orally treated patients (66 women, 107 men;...

10.1161/01.cir.0000165072.01672.21 article EN Circulation 2005-05-10

Background: The Parkes error grid, which was developed in 1994, presented performance zones for blood glucose (BG) monitors with borders that were not mathematically specified at the time grid published. Methods: In this article, we (1) review history of (2) present never-before-published exact coordinates and specifications so others may produce an replica original (3) discuss our suggestions how metric should be applied. Results: new ISO15197:2013 guideline system accuracy assessment BG...

10.1177/193229681300700517 article EN Journal of Diabetes Science and Technology 2013-09-01
David C. Klonoff Guido Freckmann Stefan Pleus Boris Kovatchev David Kerr and 89 more Chui Tse Chengdong Li Michael S. D. Agus Kathleen Dungan Barbora Voglová Hagerf Jan S. Krouwer Wei-An Lee Shivani Misra Sang Youl Rhee Ashutosh Sabharwal Jane Jeffrie Seley Viral N. Shah Nam K. Tran Kayo Waki Chris Worth Tiffany Tian Rachel E. Aaron Keetan Rutledge Cindy Ho Alessandra T. Ayers Amanda Adler David Ahn Halis Kaan Aktürk Mohammed E. Al‐Sofiani Timothy S. Bailey Matt Baker Lia Bally Raveendhara R. Bannuru Elizabeth M Bauer Yong Mong Bee Julia E. Blanchette Eda Cengiz J. Geoffrey Chase Kong Y. Chen Daniel R. Cherñavvsky Mark A. Clements Gerard L. Coté Ketan Dhatariya Andjela Drincic Niels Ejskjær Juan Espinoza Chiara Fabris G. Alexander Fleming Mônica Andrade Lima Gabbay Rodolfo J. Galindo Ana María Gómez Medina Lutz Heinemann Norbert Hermanns Thanh D. Hoang Sufyan Hussain Peter G. Jacobs Johan Jendle Shashank Joshi Suneil K. Koliwad Rayhan A. Lal Lawrence A. Leiter Marcus Lind Julia K. Mader Alberto Maran Umesh Masharani Nestoras Mathioudakis Michael J. McShane Chhavi Mehta Sun Joon Moon James H. Nichols David N. O’Neal Francisco J. Pasquel Anne L. Peters Andreas Pfützner Rodica Pop‐Busui Pratistha Ranjitkar Connie M. Rhee David B. Sacks Signe Schmidt Simon M. Schwaighofer Bin Sheng Gregg D. Simonson Koji Sode Elias K. Spanakis Nicole L. Spartano Guillermo E. Umpierrez Maryam Vareth Hubert W. Vesper Jing Wang Eugene E. Wright Alan H.B. Wu Sewagegn Yeshiwas Mihail Zilbermint Michael A. Kohn

An error grid compares measured versus reference glucose concentrations to assign clinical risk values observed errors. Widely used grids for blood monitors (BGMs) have limited value because they do not also reflect accuracy of continuous (CGMs).

10.1177/19322968241275701 article EN Journal of Diabetes Science and Technology 2024-10-06

OBJECTIVE: Insulin lispro is an analog of human insulin with a faster onset and shorter duration action than regular insulin. Efficacy tolerability in continuous subcutaneous infusion (CSII) treatment were assessed open randomized crossover trial comparing insulin, both applied pumps. RESEARCH DESIGN AND METHODS: A total 113 type 1 patients (60 male, 53 female, age [mean +/- SD] 37 12 years, diabetes 19 9 years) participated this open, study. Both insulins for 4 months each the appropriate...

10.2337/diacare.22.5.784 article EN Diabetes Care 1999-05-01

OBJECTIVE—In later stages of type 2 diabetes, proinsulin and proinsulin-like molecules are secreted in increasing amounts with insulin. A recently introduced chemiluminescence assay is able to detect the uncleaved “intact” differentiate it from molecules. This investigation explored predictive value intact as an insulin resistance marker. RESEARCH DESIGN AND METHODS—In total, 48 patients diabetes (20 women 28 men, aged 60 ± 9 years [means SD], duration 5.1 3.8 years, BMI 31.2 4.8 kg/m2,...

10.2337/diacare.27.3.682 article EN Diabetes Care 2004-03-01

To use a new method to examine precisely the rotational stability of foldable hydrophobic single-piece monofocal acrylic intraocular lens (IOL) and determine whether design is suitable for toric lens.University Eye Hospital, University Giessen Marburg, Giessen, Germany.The an IOL (AcrySof SA60AT, Alcon) was evaluated using digital photographs. Two sets images in 17 eyes were taken. The first set taken immediately postoperatively other, 6 months after cataract surgery. axial position eye...

10.1016/j.jcrs.2007.01.030 article EN Journal of Cataract & Refractive Surgery 2007-04-27

Background: Continuous subcutaneous insulin infusion (CSII) by means of pump devices is considered to be one the most optimal therapies achieve treatment targets in patients with diabetes mellitus. In CSII, delivered through Teflon catheters or steel needle sets, which need renewed on a regular basis. This pilot study was performed investigate change frequency daily practice and explore potential problems that may occur when sets are used for more prolonged time than recommended up 72 hours...

10.1177/193229681000400429 article EN Journal of Diabetes Science and Technology 2010-07-01

This multicenter study was conducted to evaluate the performance of five recently introduced blood glucose (BG) monitoring (BGM) devices under daily routine conditions in comparison with YSI (Yellow Springs, OH) 2300 Stat Plus analyzer.Five hundred one diabetes patients experience self-monitoring BG were randomized use three different BGM (FreeStyle Lite® [Abbott Diabetes Care Inc., Alameda, CA], FreeStyle Freedom Lite Care], OneTouch® UltraEasy® [LifeScan Milpitas, Accu-Chek® Aviva [Roche...

10.1089/dia.2011.0170 article EN Diabetes Technology & Therapeutics 2011-12-16

To assess the efficacy and safety of saxagliptin + metformin initial combination therapy compared with or alone over 76 weeks (24-week short-term 52-week long-term extension) in treatment-naÏve type 2 diabetes mellitus patients inadequate glycaemic control.In this phase 3, parallel-group, double-blind, active-controlled study, 1306 18-77 years age (HbA1c 8.0-12.0%) were randomized to 5 mg 500 metformin, 10 placebo placebo. Blinded was titrated during 1-5 treatment period mg/day increments...

10.1111/j.1463-1326.2011.01385.x article EN Diabetes Obesity and Metabolism 2011-02-23

Summary.Technosphere/Insulin (TI) is a formulation of regular human insulin and Technosphere, new drug delivery system for pulmonary administration. The designed efficient transport across the intact respiratory epithelium into systemic circulation. We have investigated pharmacodynamic pharmacokinetic properties Technosphere/Insulin in five healthy, non-smoking volunteers. In an open, randomized, three-way crossover study, subjects received 5 IU (HI) intravenously, 10 HI subcutaneously; 100...

10.1055/s-2002-19989 article EN Experimental and Clinical Endocrinology & Diabetes 2002-02-07

19 insulin-dependent diabetes mellitus (IDDM) patients participated in a randomized double-blind crossover investigation to investigate the impact of human C-peptide on skin microvascular blood flow. The was also carried out with 10 healthy volunteers. Blood pressure, heart rate, sugar, and levels were monitored during 60-min intravenous infusion period (8 pmol kg-1 min-1) or saline solution (154 mmol liter-1 NaCl), 30 min after stopping infusion. During same time period, capillary cell...

10.1172/jci2147 article EN Journal of Clinical Investigation 1998-05-15

This study was conducted to evaluate the influence of proinsulin C-peptide on erythrocyte Na+,K+-ATPase and endothelial nitric oxide synthase activities in patients with type I diabetes. In a randomized double-blind design, ten diabetes received intravenous infusions either human or physiological saline two different occasions. infused at rate 3 pmol·min-1·kg-1 for 60 min, thereafter 10 min. At baseline after 120 laser Doppler flow (LDF) measured following acetylcholine iontophoresis mild...

10.1042/cs0980283 article EN Clinical Science 2000-02-09

To develop a psychometric questionnaire to measure psychological barriers insulin treatment in patients with type 2 diabetes.Scale development was based on principal component analyses two cross-sectional studies of insulin-naïve diabetes. The structure the developed first sample 448 and subsequently cross-validated an independent 449 patients.Analyses yielded five components that accounted for 74.5% variance 14 items led following subscales: fear injection self-testing, expectations...

10.2337/dc06-2042 article EN Diabetes Care 2007-08-28

Skin microvascular assessment has progressed to an important evaluation in patients with diabetes mellitus. This study was done evaluate a new device using micro-lightguide spectrophotometry the of skin function.Twenty nondiabetic subjects (age 46.6 +/- 14.8 years; mean SD) and 20 diabetic 59.4 8.4 years) participated repeated measurements spectrophotometry. technique allows simultaneous, noninvasive measurement blood flow hemoglobin oxygenation (SO(2)) at same anatomical area different...

10.1177/193229680800200625 article EN Journal of Diabetes Science and Technology 2008-11-01

Objectives:Blood glucose meters for patient self-measurement need to comply with the accuracy standards of ISO 15197 guideline. We investigated two new blood BG*Star and iBG*Star (Sanofi-Aventis) in comparison four other competitive devices (Accu-Chek Aviva, Roche Diagnostics; FreeStyle Freedom Lite, Abbott Medisense; Contour, Bayer; OneTouch Ultra 2, Lifescan) at different ranges a clinical setting healthy subjects patients type 1 2 diabetes. BGStar iBGStar are employ dynamic...

10.1185/03007995.2012.673479 article EN Current Medical Research and Opinion 2012-03-21
Coming Soon ...